Encyt Technologies, Inc. Announces a Potential Breakthrough Approach to Enhance Immunotherapy Treatment

MEMBERTOU, Nova Scotia, July 5, 2017 /PRNewswire/ -- Encyt Technologies, Inc., a leading biotech cancer research organization based in Nova Scotia, Canada, recently filed a series of patents for novel treatments to reverse resistance to immunotherapy using checkpoint inhibitors.    

According to Dr. William Harless, MD/PhD, and Encyt CEO: "ENCYT has been studying the expression pattern of a number of distinct cytokines following cancer treatments such as surgery and chemotherapy. Based on these patterns, we have been experimenting with therapeutic strategies to block this response as a rational treatment approach to cancer.  Working with our collaborating scientists at Queen's University, we are excited to report that our proprietary therapeutic approach has proven to be very successful at mitigating the development of drug resistance and metastasis in a very difficult to treat human pancreatic cancer cell line implanted into a heterotopic mouse xenograft model." Dr. Harless went on to explain, "We think our current therapeutic approach may also prove effective as an adjuvant therapy with immunotherapy.  This treatment can reverse a mesenchymal phenotype that is often predictive of resistance to these checkpoint blockers.  Furthermore, three of the key oncogenic signaling pathways up-regulated in cancer patients who are resistant to checkpoint inhibitors are targeted using our therapeutic approach." 

Immunotherapy treatments with checkpoint blockers have proven to be game changing cancer treatments in a number of different cancers.  But only a minority of patients will respond to these treatments, and most patients who initially respond to these treatments eventually become resistant. ENCYT has filed an additional two patents to protect their novel therapeutic strategy as an adjuvant treatment approach that might allow more patients to benefit from these often highly effective cancer treatments.

Encyt is currently seeking regulatory approval from Health Canada to conduct a clinical trial testing our therapeutic approach for the treatment of advanced Pancreatic Cancer.  Please follow the company's continued progress at www.encyt.net   

About Encyt Technologies, Inc.

Encyt Technologies, Inc. is an early stage cancer research organization focused on developing novel therapies for the treatment of cancer. The company has developed novel approaches to blocking post-treatment metastatic cancer stem cell proliferation, drug resistant phenotype development and adjunct Immunotherapy enhancement therapies. The company was founded in 2014 and is based in Nova Scotia, Canada. Encyt is funded by a small group of private investors and has received additional funding support from the Atlantic Canada Opportunities Agency ("ACOA"), the National Research Council of Canada ("NRC"), and other private philanthropic organizations.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material may contain statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Encyt Technologies, Inc. to be materially different from the statements made herein.

Public Relations Contact:
David Glass – Co-founder, Director 1-215-558-9950
[email protected]

SOURCE Encyt Technologies, Inc.

Related Links

http://www.encyt.net